ERBB2 and neoplasm: Our recent studies have demonstrated that specifically designed Seldegs can be used to deplete antibodies specific for the autoantigen, myelin oligodendrocyte glycoprotein (MOG), and the tumor target human epidermal growth factor receptor-2 (HER2).5,9 In addition, we have shown that the depletion of MOG-specific antibodies results in the amelioration of antibody-mediated disease in mice.9 However, the efficacy of Seldegs in reducing background and enhancing contrast during PET analyses in tumor-bearing mice has not been investigated.